Prime Medicine(PRME.US)

Last Updated 19:00:00 ET
longbridge loading

JonesTrading Reaffirms Their Buy Rating on Prime Medicine, Inc. (PRME)

Tip Ranks·
US
PRME
+4.77%
US
XBI
+1.07%
US
IXJ
+0.77%
Tip Ranks·
US
PRME
+4.77%
US
XBI
+1.07%
US
IXJ
+0.77%

Wedbush Keeps Their Buy Rating on Prime Medicine, Inc. (PRME)

Tip Ranks·
US
PRME
+4.77%
US
IBB
+0.85%
US
IBBQ
+0.69%
Tip Ranks·
US
PRME
+4.77%
US
IBB
+0.85%
US
IBBQ
+0.69%

Prime Medicine shares are trading lower after the company reported worse-than-expected Q1 sales results.

benzinga_article·
US
PRME
+4.77%
US
IBBQ
+0.69%
US
XBI
+1.07%
benzinga_article·
US
PRME
+4.77%
US
IBBQ
+0.69%
US
XBI
+1.07%

Prime Medicine GAAP EPS of -$0.28 misses by $0.03, revenue of $0.88M in-line

businessinsider·
US
PRME
+4.77%
US
IBBQ
+0.69%
US
LABD
-3.29%
businessinsider·
US
PRME
+4.77%
US
IBBQ
+0.69%
US
LABD
-3.29%

Prime Medicine | 8-K: FY2026 Q1 Revenue Misses Estimate at USD 856 K

Earnings Watch·
US
PRME
+4.77%
Earnings Watch·
US
PRME
+4.77%

Prime Medicine (NASDAQ:PRME) Upgraded to Sell at Wall Street Zen

Market Beat·
US
PRME
+4.77%
US
BBH
+0.85%
US
ARKG
+3.35%
Market Beat·
US
PRME
+4.77%
US
BBH
+0.85%
US
ARKG
+3.35%

Artisight Announces Agreement With UChicago Medicine to Deploy Smart Hospital Platform

Unusual Whales·
US
CMND
-6.75%
SH
CS精准医
+1.54%
US
ICUI
+1.27%
Unusual Whales·
US
CMND
-6.75%
SH
CS精准医
+1.54%
US
ICUI
+1.27%

Prime Medicine (NASDAQ:PRME) Stock Rating Lowered by Wall Street Zen

Market Beat·
US
PRME
+4.77%
US
LABU
+3.14%
US
ARKG
+3.35%
Market Beat·
US
PRME
+4.77%
US
LABU
+3.14%
US
ARKG
+3.35%
© 2026 Longbridge｜Disclaimer